Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary--medial supraclavicular irradiation in stage I-III breast cancer: the individual case review.
To assess consistency among participants in an European Organisation for Research and Treatment of Cancer (EORTC) phase III trial randomising between irradiation and no irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes, all participating institutes were invited to send data from 3 patients in each arm as soon as they started accrual. The evaluation focused on eligibility, compliance with the radiotherapy guidelines, treatment techniques and dose prescription to the IM-MS region. Nineteen radiotherapy departments provided a total of 111 cases, all being eligible. Minor discrepancies were found in the surgery and pathology data in almost half the patients. Major radiotherapy protocol deviations were very limited: 2 cases of unwarranted irradiation of the supraclavicular region and a significant dose deviation to the internal mammary region in 5 patients. The most frequently observed minor protocol deviation was the absence of delineation of the target volumes in 80% of the patients. By detecting systematic protocol deviations in an early phase of the trial, recommendations made to all the participating institutes should improve the interinstitutional consistency and promote a high-quality treatment.
Poortmans
P
P
Department of Radiotherapy, Dr. Bernard Verbeeten Instituut, PO Box 90120, 5000 LA, Tilburg, The Netherlands. poortmans.ph@bvi.nl
Kouloulias
V E
VE
Venselaar
J L
JL
Struikmans
H
H
Davis
J B
JB
Huyskens
D
D
van Tienhoven
G
G
Hurkmans
C
C
Mijnheer
B
B
Van den Bogaert
W
W
D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D015182:Lymphatic Irradiation / Q000379:methods; D011787:Quality of Health Care; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome